Select a Community
Are you sure you want to trigger topic in your Anconeus AI algorithm?
You are done for today with this topic.
Would you like to start learning session with this topic items scheduled for future?
IL-5
20%
37/188
Major basic protein
60%
112/188
IgM
1%
2/188
IL-8
6%
12/188
Interferon-gamma
11%
21/188
Select Answer to see Preferred Response
Major basic protein is released by eosinophils and causes bronchial epithelial damage in patients with atopic asthma. Asthma is an inflammatory airway disease that causes reversible airway obstruction and bronchospasm. It is commonly treated with beta-agonists, corticosteroids, and anticholinergics. Atopic (extrinsic) asthma is a type of asthma which is characterized by paroxysmal breathlessness and wheezing in young patients. It is not related to aspirin ingestion, pulmonary infections, inhalation of irritants, exercise, or stress. Eosinophils, which are activated by IL-5, appear to play a major role in the pathophysiology of the disease. Major basic protein is released by eosinophils and causes the bronchial epithelial damage characteristic of atopic asthma. Pollart et al. review the management of acute asthma exacerbations. They state that in the ambulatory and emergency department settings, the goals of treatment are correction of severe hypoxemia, rapid reversal of airflow obstruction, and reduction of the risk of relapse. Multiple doses of inhaled anticholinergic medication combined with beta2 agonists improve lung function and decrease hospitalization in school-age children with severe asthma exacerbations. D'Amato et al. review the role of anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. They state IgE antibodies are crucial immune mediators of airway inflammation in allergic atopic asthma and IgE-mediated hypersensitivity reactions are the likely mechanisms of allergen-induced airway obstruction. Therapeutic anti-IgE antibodies able to reduce free IgE levels and to block the binding of IgE have been developed and shown to be efficacious in treating atopic asthma. Incorrect: Answer 1: While IL-5 does activate eosinophils and is thus involved in the pathophysiology of atopic asthma, it does not directly cause bronchial epithelial damage. Answer 3: IgM is involved in mucosal defense and is not associated with atopic asthma. Answer 4: IL-8 is the major chemotactic factor for neutrophils and is not associated with atopic asthma. Answer 5: Interferon-gamma activated macrophages and Th1 cells. It is not associated with atopic asthma.
3.2
(5)
Please Login to add comment